Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
about
Modeling the within-host dynamics of HIV infectionTargeted DNA mutagenesis for the cure of chronic viral infectionsThe choreography of HIV-1 proteolytic processing and virion assemblyDistribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in MaturationPredictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approachColumnar deformation of human red blood cell by highly localized fiber optic Bessel beam stretcherAllosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturationThe A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase InhibitorsMultimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase InhibitorsMutations in HIV-1 gag and pol Compensate for the Loss of Viral Fitness Caused by a Highly Mutated ProteaseHIV Cell-to-Cell Spread Results in Earlier Onset of Viral Gene Expression by Multiple Infections per CellDrug-class specific impact of antivirals on the reproductive capacity of HIVAn artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activitiesHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionTransmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapyGag-Pol processing during HIV-1 virion maturation: a systems biology approachComparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypesCodelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumorThe Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve SlopeReal-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIVEfficacy and Mechanism of Action of Low Dose Emetine against Human CytomegalovirusPredicting the outcomes of treatment to eradicate the latent reservoir for HIV-1Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profileSwitching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNAAbasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures.Evolutionary dynamics of HIV at multiple spatial and temporal scales.Statistical approaches to analyzing HIV-1 neutralizing antibody assay dataSmall-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activationPreclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitorOne-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.New approaches to design HIV-1 T-cell vaccinesAn analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.Specificity of the autologous neutralizing antibody responseAllosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor bindingDamaging the Integrated HIV Proviral DNA with TALENs.Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.
P2860
Q21245370-86684A83-8ECF-4074-9966-8CFEF4A0F517Q24620150-0C745FF5-D913-4A09-8FE7-69AABF64B101Q27009643-6E318A22-7609-4128-8A69-DBAEF7010ED7Q27321347-18AD840E-24DE-44DB-8FD9-9669152D27AFQ27324340-4A7957A7-3CBE-482D-AC14-AE2ADD2A7EBDQ27335990-03F3056C-F896-4A50-9B01-6DD8E13E7AD8Q27677515-8C040FC6-62FC-460E-B132-3C7A14224BAEQ27677549-5999E9E0-81CD-43DD-BBE9-407AED333277Q27678141-644244D2-F32A-469E-BA9D-8C3F0212319AQ27679341-5D1F123B-3BDD-4A90-8E3F-FD8AE25A9104Q27681313-C92393D1-BA66-450E-BE61-5385C430541CQ28473451-06142595-A45E-4474-ABE5-3562766C2DDAQ28476748-CE2175D2-8718-41F4-88EB-0750D86F5250Q28478993-F6E293A2-6239-4D13-91FF-07E16C0BCB02Q28481276-5A29218B-8236-4F8E-ACFF-CC6B40D8A21AQ28487475-61DD60A2-BC72-4949-A41C-42AFCC65DF0AQ28533696-CA6B3A98-2D84-4D21-A140-841C63FCD83BQ28539169-6AB6302B-EC0C-4649-8FF4-1445E14D80C8Q28543911-CB72A85F-460C-40BB-952B-E3F71FFE7461Q28550441-489DD002-B8F7-4C2E-85B5-757CCEE164D0Q28551642-73ACB7F4-912D-48B3-B7FA-8D2C6AC23A7FQ28552095-4E387377-62B4-4D64-8194-27AC461DC742Q28655602-2DFF3572-EF0F-408C-9266-BA8207AAD6C8Q28729122-2506704C-BE21-4D4A-A8C8-CFEA1B27EE00Q28731610-5008276E-6D03-4CAC-BE98-7557DB937DA0Q30366821-4BB41A5F-7EB2-4B6A-B7EE-079105C4A827Q30416280-9CF9A86F-F883-4DC0-98D1-3500CBB8F465Q30784057-53532169-904A-48AE-B634-B017AAEC3DB4Q33508788-9E442AEC-82A4-4BA4-B4B8-955A93ECD336Q33797858-003DB644-3642-4272-B0DA-151DAC9ED1E9Q33807513-DAB59E7F-6EC9-4F11-90F4-D12DA2BA1C1AQ33900441-6822962C-2A56-44C1-941B-C082FF6ADFDDQ34128479-B4384088-D07F-4755-A332-8FDF77AFE66CQ34150117-DD231AB1-A2AE-4498-978E-E5054E61B905Q34274849-27B72DDC-6049-4476-BB88-C9AE3EE5B6FBQ34289422-0F50B146-8A07-4278-94E0-9662EDE26E24Q34415389-C81CAAFA-CC97-48BC-84C3-1F5900E2037EQ34439424-EC625165-C00F-4FBC-9C4E-7A88746ABC1FQ34475249-A0A7251C-DAEF-4757-B77D-6D94A4B7CA5DQ34922985-FE5A21D2-975E-415E-AB82-1323D5E01ED0
P2860
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dose-response curve slope sets ...... ry potential of anti-HIV drugs
@en
Dose-response curve slope sets ...... y potential of anti-HIV drugs.
@nl
type
label
Dose-response curve slope sets ...... ry potential of anti-HIV drugs
@en
Dose-response curve slope sets ...... y potential of anti-HIV drugs.
@nl
prefLabel
Dose-response curve slope sets ...... ry potential of anti-HIV drugs
@en
Dose-response curve slope sets ...... y potential of anti-HIV drugs.
@nl
P2093
P2860
P356
P1433
P1476
Dose-response curve slope sets ...... ry potential of anti-HIV drugs
@en
P2093
Ahmad R Sedaghat
Edward P Acosta
Eleanor Pitt
Haili Zhang
Karen S Anderson
Marc Callender
Moira A McMahon
Susan Peterson
P2860
P2888
P304
P356
10.1038/NM1777
P407
P577
2008-06-15T00:00:00Z